Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone

Παρόμοια τεκμήρια

• Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
  ανά: Keystone, Edward C, κ.ά.
  Έκδοση: (2018)
• Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
  ανά: Kavanaugh, Arthur, κ.ά.
  Έκδοση: (2018)
• Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
  ανά: Kavanaugh, Arthur, κ.ά.
  Έκδοση: (2013)
• Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
  ανά: Smolen, Josef S, κ.ά.
  Έκδοση: (2018)
• Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
  ανά: Burmester, Gerd R, κ.ά.
  Έκδοση: (2017)